HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...

Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...

Moderna is counting on new mRNA products such as its experimental COVID-flu combo shot to offset slumping COVID vaccine sales ...

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

The emerging technology promises better medicine, faster internet and more sustainable food production. It also comes with ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Exxon Mobil CEO Darren Woods said the oil giant is looking for acquisition opportunities in the oil-and-gas space after losing its challenge to Chevron's $53 billion deal to buy Hess. Wal-Mart de ...

Stocks fell sharply Friday as investors responded to President Donald Trump's latest moves on tariffs and an employment ...

A barrage of weak economic data and the announcement of a whole new set of US import tariffs weighed heavily on Wall Street on Friday, with stocks finishing the week with heavy losses.

Moderna's (NASDAQ:MRNA) quarter was okay on the numbers, but the stock slid because the company pulled back its full-year ...

The reduction of people getting COVID vaccines is hitting Moderna. It plans to cut some of its workforce by the end of the year.